8-K: INmune Bio Inc. Presents Preliminary Phase I/II Trial Results for INKmune in Metastatic Prostate Cancer

INmune Bio Inc. shared preliminary results from its Phase I/II trial of INKmune in metastatic, castration-resistant prostate cancer (mCRPC) at the Innate Killer Summit in March 2025, highlighting safety and potential immunologic efficacy.

Summary

• INmune Bio Inc. presented a slide deck regarding their INKmune Phase I/II trial in metastatic, castration-resistant prostate cancer (mCRPC).
• The presentation included forward-looking statements about the company's business strategy, future operating results, and liquidity.
• INKmune aims to activate mINK cells to target tumors.
• The trial design involves dose escalation (1x10^8, 3x10^8, 5x10^8) to determine the effective and safe dose.
• The trial is assessing short and long-term safety, immunologic efficacy (conversion of NK cells to mlNK cells), and anti-tumor effects.
• All Phase I doses have been administered, with no serious adverse events reported after 29 infusions in 10 patients.
• Phase II is open at intermediate and high doses, with two patients treated at the intermediate level.
• CMC (Chemistry, Manufacturing, and Controls) is completed for all future doses.
• Immune response data is being compiled, and PSMA-PET data has been received for pre-treatment, Day 57, and Day 169 timepoints.
• Preliminary data suggests NK activation in vivo, even at the lowest dose, and transient effects on tumor lesions.
• The company is exploring repeat dosing strategies and suitability for early intervention in disease management.

Sentiment

Score: 7

Explanation: The document presents positive preliminary safety data and evidence of NK cell activation, suggesting potential for the therapy. However, the lack of consistent PSA response and transient effects on tumor lesions temper the enthusiasm.

Positives

• The primary safety endpoint of the Phase I portion of the trial has been met.
• There is evidence of NK cell activation in vivo, even at the lowest dose.
• Transient effects on tumor lesions, particularly in lymph node metastases, have been observed.
• CMC is completed for all future doses, ensuring consistent manufacturing.
• The trial design includes assessments of immunologic efficacy and anti-tumor effects.

Negatives

• The presentation notes that there was no consistent effect on PSA levels.
• High level disease burden is probably unresponsive.
• The effects on tumor lesions are described as transient.

Risks

• The forward-looking statements are subject to uncertainties, risks, and changes in circumstances that are difficult to predict.
• The company's ability to raise capital to fund continuing operations is a risk factor.
• Competition from other providers and products could impact the company's success.
• Changes in government regulation could affect the development and commercialization of products.
• The company's ability to protect its intellectual property rights is a risk.

Future Outlook

The company is exploring repeat dosing strategies and suitability for early intervention in disease management. The trial will determine the effective dose, short and long-term safety, immunologic efficacy, and anti-tumor effects of INKmune.

Industry Context

This announcement relates to the field of immuno-oncology, specifically the use of NK cell activation to treat cancer. It is part of a broader trend in developing therapies that harness the body's immune system to fight tumors.

Comparison to Industry Standards

• The approach of using NK cell activation is similar to that of companies like Fate Therapeutics and Nkarta Therapeutics, which are also developing NK cell-based cancer therapies.
• The Phase I/II trial design is standard for early-stage clinical development of novel therapeutics.
• The endpoints being assessed (safety, immunologic efficacy, anti-tumor effects) are typical for this type of trial.
• The focus on metastatic castration-resistant prostate cancer aligns with the unmet need for new treatment options in this patient population.

Stakeholder Impact

• Positive results could benefit shareholders through increased stock value.
• Successful development of INKmune could provide a new treatment option for patients with mCRPC.
• Positive trial outcomes could enhance the company's reputation and attract partnerships.

Next Steps

• Continue enrollment in Phase II of the CARE-PC trial at intermediate and high doses.
• Compile and analyze immune response data.
• Analyze ctDNA data.
• Present CARE-PC data.

Key Dates